IRON vs IRWD
IRON: Disc Medicine is a clinical-stage biopharmaceutical firm advancing a pipeline of novel therapies to treat serious hematologic and red blood cell disorders by targeting heme biosynthesis and iron homeostasis. IRWD: Ironwood Pharmaceuticals is a GI-focused biotech company commercializing the market-leading treatment for IBS-C and CIC, LINZESS, while advancing its late-stage pipeline asset for short bowel syndrome.
Side-by-side fundamentals
| Metric | IRON | IRWD | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $76.00 | $3.55 | |
| Market cap | $2.9B | $587M | |
| P/E as of 2026-10-21 | n/a | 4.49 | |
| Net margin FY2025, SEC XBRL | n/a | +8.1% | |
| Operating margin FY2025, SEC XBRL | n/a | +33.3% | |
| ROE FY2025, SEC XBRL | -28.7% | n/a | |
| ROA FY2025, SEC XBRL | -26.3% | +6.1% | IRWD higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.09 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | n/a | -15.7% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -10.3% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.16 | 1.19 | |
| 1-year return as of 2026-10-21 close | -11.8% | +127.6% | IRWD higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.